Journal article
Infliximab as a second‐line therapy for children with refractory Kawasaki disease: A systematic review and meta‐analysis of randomized controlled trials
Abstract
AIMS: Infliximab is a tumour necrosis factor-alpha inhibitor that is used to treat children with refractory Kawasaki disease (KD). Our purpose was to evaluate the safety and impact of infliximab versus intravenous immunoglobulins on the incidence of coronary artery aneurysms (CAAs) and treatment resistance in children with refractory KD.
METHODS: The Medline/PubMed, Embase, CINAHL, Cochrane Central Register of Controlled Trials and clinical …
Authors
Kabbaha S; Milano A; Aldeyab MA; Thorlund K
Journal
British Journal of Clinical Pharmacology, Vol. 89, No. 1, pp. 49–60
Publisher
Wiley
Publication Date
1 2023
DOI
10.1111/bcp.15547
ISSN
0306-5251